Nivolumab biosimilar (Beijing Kawin Technology Share-Holding)

纳武利尤单抗生物类似药（凯因科技）

Report date: 2025/02/18 11:33:17

Base Information

Drug NameNivolumab biosimilar (Beijing Kawin Technology Share-Holding)

Drug Alias Namebiosimilar PD-1 checkpoint inhibitor (Beijing Kawin Technology Share-holding)biosimilar anti-PD-1 antibody (Beijing Kawin Technology Share-holding)KW-019

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionProgrammed cell death protein 1 blockers

TargetsProgrammed cell death protein 1

Therapy Area/IndicationsNeoplasmsHepatitis B

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaPending

Originator CompaniesBeijing Kawin Technology Share-Holding Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBeijing Kawin Technology Share-Holding Co Ltd

Active IndicationsN/A

Inactive IndicationsNeoplasmsHepatitis B

Other Information

ATC CodeN/A